Abstract
Hyperglycemia recognized during hospitalization for acute coronary syndromes (ACS) is common. It is a powerful predictor of worse prognosis in patients both with and without previously known diabetes mellitus. Hyperglycemia during ACS is caused by an inflammatory and adrenergic response to ischemic stress, when catecholamines are released and glycogenolysis induced. The link between hyperglycemia and prognosis in ACS patients is multi-factorial. Hyperglycemia exerts detrimental effects on left ventricular and platelet function and it also activates other systemic pathological processes that contribute to cellular and tissue injury such as increasing oxidative stress and worsening endothelial function. Glucose management strategies in ACS may improve outcome in patients with hyperglycemia, by reducing inflammatory and clotting mediators, by improving endothelial function and fibrinolysis and by reducing infarct size. Most of available oral anti-diabetic drugs are contraindicated for the increased risk of hypoglycemia. Thus, insulin is the preferred agent for glycemic control in ACS and conversion from intravenous to subcutaneous therapy commonly occurs when the critical acute phase of ACS resolves. Pharmacodynamics of insulin allows it to be adaptable to the changing physiology of the ACS patient, is easily titrated and has no dosage threshold. Nevertheless, findings concerning the effect on ACS-related mortality of the control of glucose levels by intravenous infusion of insulin have been conflicting and intervention trials are needed to optimize the definition of hyperglycemia and to establish appropriate modalities and goals of glucose lowering treatment. In particular, the clinical benefit of an aggressive treatment with insulin is yet unproved.
Keywords: Acute coronary syndrome, glycemic control, hyperglycemia, myocardial infarction, prognosis.
Mini-Reviews in Medicinal Chemistry
Title:Detrimental Effects of Hyperglycemia in Acute Coronary Syndromes: from Pathophysiological Mechanisms to Therapeutic Strategies
Volume: 15 Issue: 14
Author(s): Fabio Angeli, Gianpaolo Reboldi, Cristina Poltronieri, Adolfo Aita, Claudia Bartolini and Paolo Verdecchia
Affiliation:
Keywords: Acute coronary syndrome, glycemic control, hyperglycemia, myocardial infarction, prognosis.
Abstract: Hyperglycemia recognized during hospitalization for acute coronary syndromes (ACS) is common. It is a powerful predictor of worse prognosis in patients both with and without previously known diabetes mellitus. Hyperglycemia during ACS is caused by an inflammatory and adrenergic response to ischemic stress, when catecholamines are released and glycogenolysis induced. The link between hyperglycemia and prognosis in ACS patients is multi-factorial. Hyperglycemia exerts detrimental effects on left ventricular and platelet function and it also activates other systemic pathological processes that contribute to cellular and tissue injury such as increasing oxidative stress and worsening endothelial function. Glucose management strategies in ACS may improve outcome in patients with hyperglycemia, by reducing inflammatory and clotting mediators, by improving endothelial function and fibrinolysis and by reducing infarct size. Most of available oral anti-diabetic drugs are contraindicated for the increased risk of hypoglycemia. Thus, insulin is the preferred agent for glycemic control in ACS and conversion from intravenous to subcutaneous therapy commonly occurs when the critical acute phase of ACS resolves. Pharmacodynamics of insulin allows it to be adaptable to the changing physiology of the ACS patient, is easily titrated and has no dosage threshold. Nevertheless, findings concerning the effect on ACS-related mortality of the control of glucose levels by intravenous infusion of insulin have been conflicting and intervention trials are needed to optimize the definition of hyperglycemia and to establish appropriate modalities and goals of glucose lowering treatment. In particular, the clinical benefit of an aggressive treatment with insulin is yet unproved.
Export Options
About this article
Cite this article as:
Angeli Fabio, Reboldi Gianpaolo, Poltronieri Cristina, Aita Adolfo, Bartolini Claudia and Verdecchia Paolo, Detrimental Effects of Hyperglycemia in Acute Coronary Syndromes: from Pathophysiological Mechanisms to Therapeutic Strategies, Mini-Reviews in Medicinal Chemistry 2015; 15 (14) . https://dx.doi.org/10.2174/1389557515666150722111341
DOI https://dx.doi.org/10.2174/1389557515666150722111341 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
Call for Papers in Thematic Issues
Bioprospecting of Natural Products as Sources of New Multitarget Therapies
According to the Convention on Biological Diversity, bioprospecting is the exploration of biodiversity and indigenous knowledge to develop commercially valuable products for pharmaceutical and other applications. Bioprospecting involves searching for useful organic compounds in plants, fungi, marine organisms, and microorganisms. Natural products traditionally constituted the primary source of more than ...read more
Computational Frontiers in Medicinal Chemistry
The thematic issue "Computational Frontiers in Medicinal Chemistry" provides a robust platform for delving into state-of-the-art computational methodologies and technologies that significantly propel advancements in medicinal chemistry. This edition seeks to amalgamate top-tier reviews spotlighting the latest trends and breakthroughs in the fusion of computational approaches, including artificial intelligence (AI) ...read more
Natural Products and Dietary Supplements in Alleviation of Metabolic, Cardiovascular, and Neurological Disorders
Metabolic disorders like diabetes, obesity, inflammation, oxidative stress, cancer etc, cardiovascular disorders like angina, myocardial infarction, congestive heart failure etc as well as neurological disorders like Alzheimer?s, Parkinson?s, Epilepsy, Depression, etc are the global burden. They covered the major segment of the diseases and disorders from which the human community ...read more
Natural Products in Drug Discovery
Natural products have always been one of the important ways of drug discovery due to their novel skeleton and diverse functional group characteristics. According to statistics, between 1981 and 2019, the FDA approved a total of 1,394 small molecule drugs for marketing, of which 930 marketed drugs originated from the ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Current Advances in Therapy for Metastatic Melanoma
Current Cancer Therapy Reviews Enhanced Tolerance against Early and Late Apoptotic Oxidative Stress in Mammalian Neurons through Nicotinamidase and Sirtuin Mediated Pathways
Current Neurovascular Research Subcellular Analysis of the Platelet Proteome
Current Proteomics Potential Anti-cancer Drugs Commonly Used for Other Indications
Current Cancer Drug Targets Contribution of ALDH2 Polymorphism to Alcoholism-Associated Hypertension
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Fixed-Ratio Combinations of Basal Insulin and GLP-1RA in the Management of Type 2 Diabetes Mellitus: Highlights from the Literature
Endocrine, Metabolic & Immune Disorders - Drug Targets Human Carbonyl Reductases
Current Drug Metabolism Cardiovascular Diseases and the Nitric Oxide Pathway
Current Vascular Pharmacology Hypoxia-inducible Factor-1α Mediates Hyperglycemia-induced Pancreatic Cancer Glycolysis
Anti-Cancer Agents in Medicinal Chemistry Syntheses, Transformations and Pharmaceutical Applications of Kynurenic Acid Derivatives
Current Medicinal Chemistry Innate Immunity Alterations in Type 2 Diabetes Mellitus: Understanding Infection Susceptibility
Current Molecular Medicine A Review of Type 2 Diabetes Mellitus Predisposing Genes
Current Diabetes Reviews Preparation and Evaluation of Multi Particulates Drug Delivery System Using Natural Polymers
Current Drug Delivery Chromogranin-A: A Multifaceted Cardiovascular Role in Health and Disease
Current Medicinal Chemistry Treatment of HCV-Related Mixed Cryoglobulinemia
Current Drug Targets GABAergic Modulation in Diabetic Encephalopathy-Related Depression
Current Pharmaceutical Design How Should We Treat Hypertension and Dyslipidemia in Patients with Prediabetes?
Current Pharmaceutical Design Menstrual Cycle and Glycemic Control
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery The Role of Sympathetic Nervous System in the Progression of Chronic Kidney Disease in the Era of Catheter Based Sympathetic Renal Denervation
Current Clinical Pharmacology Severe Influenza: Clinical Features and Treatment Options
Current Respiratory Medicine Reviews